

# PATENT COOPERATION TREATY

RECEIVED

27 JUN 2005 MAR 17 2005

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:  
JANE MASSEY LICATA  
LICATA & TYRRELL P.C.  
66 E. MAIN STREET  
MARLTON, NJ 08053

Docket System ✓  
Status Report ✓  
Docket Book ✓

NP = 6/27/05

**PCT**

NOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing  
(day/month/year)

**15 MAR 2005**

Applicant's or agent's file reference

UMD-0019

**IMPORTANT NOTIFICATION**

International application No.

PCT/US03/41136

International filing date (day/month/year)

24 December 2003 (24.12.2003)

Priority date (day/month/year)

27 December 2002 (27.12.2002)

Applicant

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Mail Stop PCT, Attn: IPEA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

*Carla Myers*  
Carla Myers

Telephone No. 571-272-1600


Form PCT/IPEA/416 (July 1992)

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>UMD-0019</b>	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/US03/41136</b>	International filing date (day/month/year) <b>24 December 2003 (24.12.2003)</b>	Priority date (day/month/year) <b>27 December 2002 (27.12.2002)</b>	
International Patent Classification (IPC) or national classification and IPC <b>IPC(7): C12Q 1/68; C12P 19/34; C07H 21/02, 21/04 and US Cl.: 435/6, 91.1, 91.2; 536/23.1, 24.3, 24.31</b>			
Applicant <b>UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY</b>			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>5</u> sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>2</u> sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand <b>20 July 2004 (20.07.2004)</b>		Date of completion of this report <b>14 February 2005 (14.02.2005)</b>	
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer  Carla Myers Telephone No. 571-272-1600	

Form PCT/IPEA/409 (cover sheet)(July 1998)

**I. Basis of the report****1. With regard to the elements of the international application:\***☐

the international application as originally filed.

☒

the description:

pages 1-20 as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.☒

the claims:

pages NONE, as originally filedpages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages 21 and 22, filed with the letter of 15 November 2004 (15.11.2004)☒

the drawings:

pages 1-3, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.☒

the sequence listing part of the description:

pages 1-25, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

☐

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐

the language of publication of the international application (under Rule 48.3(b)).

☐

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☒

contained in the international application in printed form.

☒

filed together with the international application in computer readable form.

☐

furnished subsequently to this Authority in written form.

☐

furnished subsequently to this Authority in computer readable form.

☐

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☐ The amendments have resulted in the cancellation of:**☐the description, pages NONE☐the claims, Nos. NONE☐the drawings, sheets/fig NONE**5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.  
PCT/US03/41136

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. STATEMENT**

Novelty (N)	Claims <u>1-11</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-11</u>	NO
Industrial Applicability (IA)	Claims <u>1-11</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Please See Continuation Sheet

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

**V. 2. Citations and Explanations:**

Claims 1, 2, 4-6, and 8-10 lack an inventive step under PCT Article 33(3) as obvious over Nazarenko in view of Metallinos and Matsuzaki. Nazarenko (see column 25) teaches a method for detecting the presence of a single nucleotide polymorphism or a mutation in a target nucleic acid wherein the method comprises: (i) amplifying a nucleic acid sequence using a hairpin primer, wherein the primer terminates at a polymorphic position; and (ii) measuring the amount of amplification product wherein a decrease in the amplification product is indicative of the presence of a polymorphism or mutation. Nazarenko (column 25) teaches that in the method of allele specific PCR, "(u)nder the appropriate reaction conditions, the target DNA is not amplified if there is a base mismatch." With respect to claims 5 and 6, Nazarenko (column 16) teaches that the hairpin primer may be DNA or RNA. With respect to claims 8-10, Nazarenko (column 32) teaches kits comprising the reagents necessary to perform allele specific PCR wherein the kits comprise a hairpin primer that terminates at its 3' end at the location of a single nucleotide polymorphism or mutation. Nazarenko is silent with respect to the length of the amplification products synthesized by the polymerase chain reaction. However, Matsuzaki teaches that PCR is more efficient when smaller length nucleic acids are amplified. The reference (column 1) states that "The yield of longer amplicons is often less than the yield of shorter amplicons because of those differences in PCR amplification efficiency." Further, Metallinos (column 11) exemplifies methods of allele specific PCR in which the amplification products are of a length of 90 bp. In view of the teachings of Matsuzaki and Metallinos, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of Nazarenko so that PCR primers were selected to yield products of a smaller length, e.g., products of a length of 90 nucleotides or less, in order to have improved the efficiency of PCR and to have increased the yield of the target amplification product.

Claims 3, 7 and 11 lack an inventive step under PCT Article 33(3) as obvious over Nazarenko in view of Metallinos and Matsuzaki and further in view of Tyagi. The teachings of Nazarenko, Metallinos and Matsuzaki are presented above. With respect to claim 3, Nazarenko teaches detecting PCR amplification products at the completion of the PCR assay. Nazarenko does not teach detecting PCR products using real-time PCR. However, Tyagi teaches a method of allele specific PCR (column 3) wherein amplification products are measured either in real-time or at the end-point of the assay (column 4). Tyagi teaches that the primer used for PCR may be a hairpin primer (column 6). Tyagi (column 2) also teaches that "if the binding of the primer in the tube to the target sequence creates a mismatched 3'-terminal nucleotide, then the primer cannot be efficiently extended by incubation with DNA polymerase. Amplification of the mismatched template is significantly delayed." In view of the teachings of Tyagi, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Nazarenko so as to have detected the amplification products in real-time, rather than at the completion of PCR, because Tyagi teaches that real-time PCR provides an equally effective means for monitoring allele-specific amplification.

With respect to claims 7 and 11, Nazarenko does not teach performing allele-specific PCR using hairpin primers that contain PNAs. However, Tyagi (column 6) teaches that hairpin primers used for allele specific PCR may contain PNAs. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Nazarenko so as to

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.  
PCT/US03/41136

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

have performed the allele-specific PCR method using hairpin primers that contain PNAs in view of the well known benefits provided by PNAs of enhancing the stability of hybridization and improving the ability to distinguish between perfectly matched and mismatched sequences. Thereby, one would have been motivated to have used PNA hairpin primers in order to have provided a more sensitive and effective method for detecting the presence of a polymorphism or mutation.

Claims 1-11 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry for detecting the presence of a mutation or polymorphism in a target nucleic acid.

In the response filed November 15, 2004, the previous rejection was traversed. The response states that the claims have been amended to recite that the amplification product is of a length of 30 to 90 nucleotides, and that the cited prior art does not teach this embodiment. However, as set forth in the above rejection, the concept of producing smaller amplification products was known in the art as exemplified by the teachings of Metallinos and Matsuzaki. In view of the teachings of Metallinos and Matsuzaki, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have practiced the method of Nazarenko using PCR primers that yield smaller amplification products of a length of about 90 nucleotides or length in order to have increased the efficiency of PCR.

NEW CITATIONS

US 6,333,179 B1 (MATSUZAKI et al) 25 December 2001 (25.12.2001), see column 1.  
US 6,372,900 B1 (METALLINOS et al) 04 April 2002 (16.04.2002), see column 11.